Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
synthetic cannabinoid |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:Health_Canada 1981 |
| gptkbp:ATCCode |
gptkb:A04AD11
|
| gptkbp:CASNumber |
gptkb:51022-71-6
|
| gptkbp:chemicalFormula |
C24H36O3
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:eliminationHalfLife |
2 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
nabilona
|
| gptkbp:legalStatus |
gptkb:Schedule_II_(US)
prescription only |
| gptkbp:marketedAs |
gptkb:Cesamet
|
| gptkbp:mechanismOfAction |
cannabinoid receptor agonist
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
10432
|
| gptkbp:relatedTo |
gptkb:dronabinol
gptkb:tetrahydrocannabinol |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
drowsiness euphoria dry mouth |
| gptkbp:UNII |
gptkb:6M3C89ZY6R
|
| gptkbp:usedFor |
chemotherapy-induced nausea and vomiting
|
| gptkbp:bfsParent |
gptkb:nabilone
|
| gptkbp:bfsLayer |
7
|